The Company submitted an sNDA for ZORYVE foam for scalp and body psoriasis to the FDA based on the positive results from the pivotal ARRECTOR Phase 3 trial and a Phase 2b trial, which was accepted by ...

Objective: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor.

Dermatologists are practicing in an “era of good efficacy” of nonsteroidal topical therapies for psoriasis, and they can help patients access newer topical medications by working with pharmacies that ...

Viagra improves erections in over 80% of men taking 100 mg, it takes an average of 36 minutes to work, with effects lasting ...

Orismilast may be an effective and safe novel treatment option for adult patients with moderate to severe atopic dermatitis.

COLUMBUS — The Ohio Department of Agriculture has announced the following recalls.

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

WE’VE all been there: faced with a health issue we’re too embarrassed to talk about. Whether it’s your feet smelling bad no ...

CAPLYTA net product sales grew to $199.2 million, representing a 51%increase over the same period in 2023Full year 2024 ...

The global benign prostatic hyperplasia (BPH) prostate treatment market is projected to grow from USD 33.03 billion in 2024 ...

After hours: February 21 at 5:51:03 PM EST Loading Chart for ANRO ...